Erratum: Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube.

This corrects the article on p. e43 in vol. 29, PMID: 29770616.

The original article by Choi et al. entitled, “Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube” [1] contained errors.

Both the variant nomenclature of “p.Arg67fs” in CHAPC-003 and “p.Arg67Ilefs” are suitable according to Human Genome Variation Society (HGVS) recommendation. However, we have corrected “p.Arg67fs” to “p.Arg67Ilefs” in order to represent it in a more unified form with the other frame-shift variants.

The mutation and mutation type of case CHAPC-011 was corrected “c.2808_2011delACAA” to “c.2808_2811delACAA” and “p.Lys936fs” to “p.Ala938Profs.”

The variant description of "c.2164+16->A" in the cases CHAPC-008, CHAPC-009 and CHAPC-010 is the nomenclature of Annovar algorithm which was used to annotate mutations. It was changed to “c.2164+15_2164+16insA” according to the HGVS recommendation. This variation was described as variant of uncertain significance (VUS) in this article because it was unavailable in ClinVar at the time of publication. Meanwhile, in a recently published article by Caggiari et al. [2], the reference single nucleotide polymorphisms (SNPs) ID number of this variation was mentioned as “rs35686369” and it was described as benign in ClinVar.

The variant descriptions of “p.Leu630Val-” in the case CHATC-001 was corrected to “p.Leu630Val”.

In addition, we have also inserted hyphens in ‘Double primary,’ ‘Family history,’ and ‘FH of other cancer’ columns in the Table 2.

We attached the corrected Table 2 as shown below (modified values were underlined, except error 5).

Table 2. Detected germline mutations and VUS of BRCA1/2, TP53, PTEN, CDH1, PALB2 genes in PC/FTC patients

FH, family history; FTC, fallopian tube cancer; PC, primary peritoneal cancer; VUS, variants of unknown clinical significance.

*Breast cancer history of patient's own, †Family history of BRCA-related cancer within second degree relatives.